<i>EGFR</i> Status Assessment for Better Care of Early Stage Non-Small Cell Lung Carcinoma: What Is Changing in the Daily Practice of Pathologists?
The recent emergence of novel neoadjuvant and/or adjuvant therapies for early stage (I-IIIA) non-small cell lung carcinoma (NSCLC), mainly tyrosine kinase inhibitors (TKIs) targeting <i>EGFR</i> mutations and immunotherapy or chemo-immunotherapy, has suddenly required the evaluation of b...
Main Author: | Paul Hofman |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/10/8/2157 |
Similar Items
-
First-Line EGFR-TKIs Treatment in Stage I Non-Small-Cell Lung Cancer Patients Harboring EGFR Gene Mutations with Postoperative Intrapulmonary Recurrence
by: Zhu Z, et al.
Published: (2021-02-01) -
Targeted Assessment of the <i>EGFR</i> Status as Reflex Testing in Treatment-Naive Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France)
by: Sandra Lassalle, et al.
Published: (2020-04-01) -
Dynamic Evaluation of Circulating miRNA Profile in <i>EGFR</i>-Mutated NSCLC Patients Treated with EGFR-TKIs
by: Alessandro Leonetti, et al.
Published: (2021-06-01) -
The Factors Predicting Concordant Epidermal Growth Factor Receptor (EGFR) Mutation Detected in Liquid/Tissue Biopsy and the Related Clinical Outcomes in Patients of Advanced Lung Adenocarcinoma with <i>EGFR</i> Mutations
by: Chia-Yu Kuo, et al.
Published: (2019-10-01) -
Diffuse Lung Metastases in <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer
by: Subba R. Digumarthy, et al.
Published: (2019-09-01)